2 highly-rated ASX growth shares to buy

Here’s why Ltd (ASX:KGN) and this ASX growth share have been tipped as the ones for investors to buy right now…
The post 2 highly-rated ASX growth shares to buy appeared first on The Motley Fool Australia. –

thumbs up

If you’re wanting to boost your portfolio with some quality growth shares, then you might want to take a look at the ones listed below.

Here’s why these quality ASX growth shares have been tipped as ones to buy right now: Ltd (ASX: KGN)

The first ASX growth share to consider buying is Kogan. While this ecommerce company was already growing at a strong rate prior to the pandemic, its growth went up several gears after COVID accelerated the structural shift to online shopping.

This has underpinned an exceptionally strong first half performance. For example, Kogan recently released its half year update and revealed a 96% increase in gross sales over the prior corresponding period.

But perhaps even better, is that its margins have been expanding. As a result, Kogan’s gross profit grew over 120% and its earnings before interest, tax, depreciation and amortisation (EBITDA) jumped over 140%.

While the worst of the pandemic is now behind us, the shift to online shopping still has a long way to go. This should mean Kogan benefits from this tailwind for some time to come.

Credit Suisse currently has an outperform rating and $21.08 price target on its shares.

ResMed Inc. (ASX: RMD)

A second ASX growth share to look at is ResMed. This sleep treatment-focused medical device company has been benefiting from tailwinds of its own over the last decade. The key one being the growing awareness of sleep disorders such as sleep apnoea.

This has underpinned very strong demand for ResMed’s industry-leading portfolio of products. Positively, with the majority of sleep apnoea sufferers still undiagnosed, the company still has a huge runway for growth over the next few decades.

In addition to this, ResMed has been tipped as a company that will benefit greatly from a shift to home healthcare. This is thanks partly to some smart investments in the out of hospital space over the last few years. This includes its US$800 million acquisition of Brightree in 2016.

Credit Suisse is also a fan of ResMed. It currently has an outperform rating and $29.50 price target on the company’s shares.

Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

See The 5 Stocks

*Returns as of February 15th 2021

More reading

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of ltd. The Motley Fool Australia has recommended ltd and ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post 2 highly-rated ASX growth shares to buy appeared first on The Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!